Latest by Polly Clayden
While antiretroviral therapy in pregnancy reduced vertical transmission, it also increased the frequency of several adverse birth outcomes compared with antenatal zidovudine (AZT) alone.
Women on Lopinavir/Ritonavir-Based Regimens at Conception at Higher Risk of Preterm Delivery in UK Study
HIV-positive pregnant women receiving lopinavir/ritonavir-based regimens were at higher risk of preterm delivery compared with those on NNRTI-based regimens.
Among pregnant women with HIV in the PROMISE trial, use of TDF/FTC/LPV/r was not associated with increased risk of adverse infant birth outcomes when compared to AZT/3TC/LPV/r or TDF/FTC/ATV/r.
Researchers compared birth outcomes with in-utero exposure from conception to the five most common antiretroviral therapy regimens used in Botswana.
Dolutegravir exposure was higher after crushing the originator fixed-dose combination tablet and after crushing was followed by enteral nutrition, compared to the whole tablet.
Dolutegravir granules-in-suspension achieved satisfactory exposures in children aged between 2 and 6 years, according to data presented at CROI2017.
Dolutegravir-Based ART in Combination With Rifampicin-Based TB Treatment Is Safe in a Small Cohort of Co-Infected Patients
Twice daily dolutegravir in combination with rifampicin was well tolerated and produced good outcomes in a small retrospective study presented at HIV Drug Therapy Glasgow 2016.
Five case studies from Uganda showed good responses in children and adolescents receiving raltegravir-based third-line ART.
Virological Response Without Routine Viral Load Monitoring in Children: Results From the ARROW Trial
Reassuring virological outcomes without routine viral load monitoring shown in the ARROW trial but viral rebound greater than 5000 copies/mL should prompt switch to second-line, according to data presented 8th International Workshop on HIV Paediatric...
A systematic review and meta-analysis, conducted to inform the new World Health Organization Consolidated Guidelines, found dolutegravir superior to standard dose efavirenz for both viral suppression and discontinuation rates.